Curated News
By: NewsRamp Editorial Staff
November 12, 2024

Tonix Pharmaceuticals Reports Q3 2024 Financial Results and Advances Drug Pipeline

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackView History of this news story on GitHub Github
Source News Release

TLDR

  • Tonix Pharmaceuticals reported submitting an NDA for TNX-102 SL, a potential fibromyalgia treatment, with Fast Track designation to expedite review.
  • Tonix is advancing TNX-801 mpox vaccine and TNX-1300 for cocaine intoxication treatment, aligning with WHO targets for infectious disease and CNS disorder treatments.
  • Tonix's commitment to advancing treatments for CNS disorders and infectious diseases aims to improve public health and address critical medical needs globally.
  • Tonix Pharmaceuticals is making strides in developing innovative treatments for fibromyalgia, mpox vaccines, and cocaine intoxication, showcasing cutting-edge biopharmaceutical research.

Impact - Why it Matters

This news matters as it highlights the progress and commitment of Tonix Pharmaceuticals in developing innovative treatments for fibromyalgia, mpox vaccines, and cocaine intoxication. The Fast Track designation from the FDA for TNX-102 SL showcases the potential impact of these treatments on patients with central nervous system disorders and infectious diseases.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) reported its third-quarter 2024 financial results, highlighting the submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (FDA) for TNX-102 SL, a potential treatment for fibromyalgia. The FDA granted TNX-102 SL Fast Track designation in the third quarter of 2024, aiming to expedite the review process for this non-opioid analgesic. Additionally, Tonix is progressing with TNX-801, a potential mpox vaccine, aligning with the World Health Organization’s target product profile for mpox vaccines. The company also announced the enrollment of the first patient in the Phase 2 CATALYST study of TNX-1300 for cocaine intoxication treatment. These developments underscore Tonix’s commitment to advancing treatments for central nervous system disorders and infectious diseases.

Source Statement

This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Tonix Pharmaceuticals Reports Q3 2024 Financial Results and Advances Drug Pipeline

blockchain registration record for the source press release.